These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 22938159

  • 1. Early findings of prospective anti-HLA donor specific antibodies monitoring study in pancreas transplantation: Indiana University Health Experience.
    Mujtaba MA, Fridell JA, Higgins N, Sharfuddin AA, Yaqub MS, Kandula P, Chen J, Mishler DP, Lobashevsky A, Book B, Powelson J, Taber TE.
    Clin Transplant; 2012; 26(5):E492-9. PubMed ID: 22938159
    [Abstract] [Full Text] [Related]

  • 2. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
    Cooper JE, Gralla J, Chan L, Wiseman AC.
    Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
    [Abstract] [Full Text] [Related]

  • 3. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM, Patel SJ, Burns KM, Dilioglou S, Gaber LW, Knight RJ, Gaber AO, Land GA.
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [Abstract] [Full Text] [Related]

  • 4. Long-term post transplant alloantibody monitoring: a single center experience.
    Ntokou IS, Boletis JN, Apostolaki M, Vrani V, Zavos G, Kostakis A, Iniotaki A.
    Clin Transpl; 2011; ():341-50. PubMed ID: 22755429
    [Abstract] [Full Text] [Related]

  • 5. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
    Leone JP, Bowers V, Baliga R, Sanders C, LeFor W, Becker D, Thompson D, Resto-Ruiz S, Lopez-Cepero M.
    Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
    [Abstract] [Full Text] [Related]

  • 6. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
    Ntokou IS, Iniotaki AG, Kontou EN, Darema MN, Apostolaki MD, Kostakis AG, Boletis JN.
    Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
    [Abstract] [Full Text] [Related]

  • 7. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC, Ozawa M.
    Clin Transpl; 2007 Nov; ():219-26. PubMed ID: 18642453
    [Abstract] [Full Text] [Related]

  • 8. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
    Caro-Oleas JL, González-Escribano MF, González-Roncero FM, Acevedo-Calado MJ, Cabello-Chaves V, Gentil-Govantes MÁ, Núñez-Roldán A.
    Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
    [Abstract] [Full Text] [Related]

  • 9. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P, Jin J, Everly MJ, Lin C, Terasaki PI, Chen J.
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [Abstract] [Full Text] [Related]

  • 10. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
    Rebellato LM, Everly MJ, Haisch CE, Ozawa M, Briley KP, Parker K, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC.
    Clin Transpl; 2011 Oct; ():337-40. PubMed ID: 22755428
    [Abstract] [Full Text] [Related]

  • 11. Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation.
    Kanter Berga J, Pallardo Mateu LM, Beltran Catalan S, Puig Alcaraz N, Sancho Calabuig A, Gavela Martinez E, Avila Bernabeu A, Crespo Albiach J.
    Transplant Proc; 2011 Oct; 43(6):2154-6. PubMed ID: 21839219
    [Abstract] [Full Text] [Related]

  • 12. Pretransplant donor-specific HLA antibodies detected by single antigen bead flow cytometry: risk factors and outcomes after kidney transplantation.
    Kanter Berga J, Sancho Calabuig A, Gavela Martinez E, Puig Alcaraz N, Beltran Catalan S, Avila Bernabeu A, Crespo Albiach J, Montoro JA, Pallardo Mateu LM.
    Transplant Proc; 2012 Nov; 44(9):2529-31. PubMed ID: 23146444
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D, Bach C, Staudner C, Böger CA, Bergler T, Banas B, Spriewald BM.
    Nephrol Dial Transplant; 2017 Apr 01; 32(4):730-737. PubMed ID: 28339671
    [Abstract] [Full Text] [Related]

  • 14. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G, Furst D, Mytilineos J, Pourmand G, Amirzargar AA.
    Transpl Immunol; 2012 Mar 01; 26(2-3):81-7. PubMed ID: 22182633
    [Abstract] [Full Text] [Related]

  • 15. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M, Torio A, Mas V, Redondo D, Pérez-Sáez MJ, Mir M, Faura A, Guerra R, Montes-Ares O, Checa MD, Pascual J.
    Transpl Immunol; 2013 Dec 01; 29(1-4):28-33. PubMed ID: 23907088
    [Abstract] [Full Text] [Related]

  • 16. Donor specific antibodies before and after kidney transplant: the University of Colorado Experience.
    Cooper JE, Gralla J, Adebiyi O, Wiseman AC, Chan L.
    Clin Transpl; 2013 Dec 01; ():407-12. PubMed ID: 25095536
    [Abstract] [Full Text] [Related]

  • 17. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
    Fidler SJ, Irish AB, Lim W, Ferrari P, Witt CS, Christiansen FT.
    Transpl Immunol; 2013 Jun 01; 28(4):148-53. PubMed ID: 23665534
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value and cost-effectiveness of different screening strategies for HLA antibodies prior to kidney transplantation.
    Ziemann M, Schönemann C, Bern C, Lachmann N, Nitschke M, Fricke L, Görg S.
    Clin Transplant; 2012 Jun 01; 26(4):644-56. PubMed ID: 22432638
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.
    Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis II, Fuggle SV, Gill J, Glotz D, Lachmann N, Mohanakumar T, Suciu-Foca N, Sumitran-Holgersson S, Tanabe K, Taylor CJ, Tyan DB, Webster A, Zeevi A, Opelz G.
    Transplantation; 2013 Jan 15; 95(1):19-47. PubMed ID: 23238534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.